Drug Profile
Ozuriftamab vedotin - BioAtla
Alternative Names: BA-3021; BA302; CAB-ROR2-ADC; HTBA-3021Latest Information Update: 17 Oct 2022
Price :
$50
*
At a glance
- Originator BioAtla
- Class Antibodies; Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates
- Mechanism of Action Cell death stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Squamous cell cancer
- Phase I/II Solid tumours
Most Recent Events
- 22 Dec 2022 Phase-II clinical trials in Squamous cell cancer (Combination therapy, Recurrent, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) (NCT05271604)
- 09 Mar 2022 BioAtla plans a phase II trial for Squamous cell cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in May 2022 (Parenteral) (NCT05271604)
- 10 Jan 2022 BioAtla enters into a clinical collaboration with Bristol Myers Squibb to investigate ozuriftamab vedotin in combination with nivolumab for solid tumours